CC-42344 Safety Study in Healthy Participants

Status Completed

Clinical Trial Summary

CC-42344 Phase 1 study with single-ascending dose (SAD) and multiple-ascending dose (MAD) parts.

Clinical Trial Description

This study is testing the safety, tolerability, and pharmacokinetics (PK, the amount of study drug in the blood) of a new drug called CC-42344.Up to 78 healthy men or women aged between 18-55 are planned to be enrolled in this study in two parts. Part 1 will involve a single-ascending (increasing) dose (SAD) where 32 participants (4 groups of 8) will be assigned randomly to receive a single oral dose of the study drug or placebo. The placebo will look the same as the study drug but will not contain any medicine. An additional 6 participants will receive a single oral dose of CC-42344 to help further understand the effect of food on the uptake of the drug. Part 2: will involve a multiple-ascending dose (MAD) where 40 participants (5 groups of 8) will be randomized to receive an oral dose of study drug or placebo given once a day for 14 days, once a day for 5 days, or twice a day for 5 days. The placebo will look the same as the study drug but will not contain any medicine. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05202379
Study type	Interventional
Source	Cocrystal Pharma, Inc.
Contact
Status	Completed
Phase	Phase 1
Start date	February 11, 2022
Completion date	March 29, 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03999554` - Safety and Immunogenicity of the Bris10 M2SR and Sing2016 M2SR H3N2 Monovalent Influenza Vaccines	Phase 1
Completed	`NCT06385821` - A Study to Prove Non-inferior Immunogenicity of Grippol Quadrivalent Compared to Grippol Plus	Phase 3
Completed	`NCT02487173` - Validation of the Respirio Flu Test for the Rapid Identification of Influenza A/B	N/A
Completed	`NCT01701752` - Influenza A Vaccine (FP-01.1) Formulated With and Without Adjuvant, in the Presence or Absence of a Single Administration of a Trivalent Inactivated Influenza Virus Vaccine in Older Adults	Phase 1
Enrolling by invitation	`NCT03207152` - Biomarkers Predicting Infectivity in an Experimental Human Influenza Model	Phase 1
Terminated	`NCT05567783` - A Phase 2 Study to Evaluate the Efficacy and Safety of VIR-2482 for the Prevention of Illness Due to Influenza A	Phase 2
Not yet recruiting	`NCT00987012` - The Influence of Fortified Pomegranate Juice (Punica Granatum) on Seasonal Influenza and Swine Flu Patients	N/A
Not yet recruiting	`NCT05928507` - FINDER® Instrument and FINDER® FLU A/B, RSV, SARS-CoV-2 Test Clinical Evaluation Protocol
Completed	`NCT03651544` - The Study of the Safety, Reactogenicity and Immunogenicity of the GamFluVac	Phase 1
Completed	`NCT02623322` - A Study of MHAA4549A as Monotherapy for Acute Uncomplicated Seasonal Influenza A in Otherwise Healthy Adults	Phase 2
Completed	`NCT03196661` - Preliminary Study on Safety and Immunogenicity of Influenza A (H7N9) Vaccine in the Population	Phase 1
Recruiting	`NCT06160531` - Influenza Viral Challenge Study of CC-42344 in Healthy Participants	Phase 2
Recruiting	`NCT06191393` - SARS-CoV-2 and Influenza A/B in Point-of-Care and Non-Laboratory Settings	N/A
Completed	`NCT06127108` - Clinical Evaluation of the Panbio™ COVID-19/Flu A&B Panel	N/A
Completed	`NCT05163730` - Clinical Evaluation of the Panbio™ COVID-19/ Flu A&B Rapid Panel	N/A
Not yet recruiting	`NCT06392451` - LIAISON NES Influenza (FLU) A/B, Respiratory Syncytial Virus (RSV), & Coronavirus Disease 2019 (COVID-19) in Symptomatic Patients in Australia	N/A
Recruiting	`NCT04896853` - Treatment of Respiratory Complications Associated With COVID19,Influenza ,Metapneumovirus,RSV Infection Using ProTrans®	Phase 1
Not yet recruiting	`NCT05787444` - Clinical Validation of the LumiraDx SARS-CoV-2 & Flu A/B Test in Detecting and Differentiating Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Influenza A (Flu A), and/or Influenza B (Flu B)
Completed	`NCT05354115` - Sample Collection for Evaluation of the Panbio™ COVID-19/ Flu A&B Rapid Panel.	N/A
Completed	`NCT02014870` - Safety and Reactogenicity of a H1N1 Influenza Challenge Virus in Healthy Volunteers	Phase 1